5 days Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy MarketWatch

   X     

1 week Biogen Q4 Earnings Review: Why I’m Calling Time On This ‘Powder Puff’ Pharma Seeking Alpha

   X     

1 week Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance Zacks

   X     

2 weeks Biogen’s Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints Zacks

   X     

2 weeks Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook Yahoo Finance

   X     

2 weeks Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma Yahoo Finance

   X     

2 weeks Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks

   X     

2 weeks Biogen Inc. 2024 Q4 – Results – Earnings Call Presentation Seeking Alpha

   X     

2 weeks Drugmaker Biogen forecasts 2025 profit below expectations Yahoo Finance

   X     

2 weeks Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat Investor's Business Daily

   X     

2 weeks Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty Investing.com

   X     

2 weeks Biogen Gears Up to Report Q4 Earnings: What’s in the Cards? Zacks

   X     

3 weeks Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks

   X     

3 weeks Biogen Stock Down on Regulatory Update in the EU for Alzheimer’s Drug Zacks

   X     

3 weeks The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics Zacks

   X     

4 weeks Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks

   X     

4 weeks Biotech Stock Roundup: SAGE Up on Declining BIIB’s Offer, CYTK, AKRO Up on Updates Zacks

   X     

4 weeks SAGE Rejects Biogen’s Offer to Buy Remaining Stake, Stock Up Zacks

   X     

4 weeks Sage rejects Biogen’s $469 million takeover offer Investing.com

   X     

4 weeks Sage rejects Biogen’s $469 million takeover offer, says offer undervalues company Yahoo Finance

   X     

4 weeks BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer’s Drug Zacks

   X     

4 weeks US FDA approves monthly maintenance dosing for Biogen/Eisai Alzheimer’s drug Investing.com

   X     

4 weeks US FDA OKs monthly maintenance dosing for Eisai/Biogen’s Alzheimer’s drug Investing.com

   X     

1 month FDA & EMA Accept Biogen’s Filings for Higher Dose SMA Drug Zacks

   X     

1 month Sage Therapeutics: Looks Like A ‘Strong Buy’ With Zurzuvae’s Potential And Biogen’s Bid Seeking Alpha

   X     

1 month Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen’s Offer & Other Updates Zacks

   X     

1 month Sage Therapeutics: Biogen’s Unsolicited Bid Is Best Step Forward For Shareholders Seeking Alpha

   X     

1 month Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) Seeking Alpha

   X     

1 month Biogen CEO sees no burning need for more acquisitions Investing.com

   X     

1 month Biogen Offers to Buy Remaining Stake in Sage Therapeutics Zacks

   X     

1 month Biogen Wants to Buy Its Partner Sage for Almost No Premium Yahoo Finance

   X     

1 month Biogen proposes to buy remaining stake in Sage in $442 million deal Investing.com

   X     

2 months Biogen Holds On, But Growth Slips Through Its Fingers Seeking Alpha

   X     

2 months Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges Investing.com

   X     

2 months Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term Zacks

   X     

2 months Beaten Down Biogen Stock Looks Attractive At Current Levels Seeking Alpha

   X     

2 months BMO cuts rating on Merck and Biogen, on lack of near term catalyst Investing.com

   X     

2 months Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead Investing.com

   X     

2 months Private Medicare plans must cover Biogen’s ALS drug, US agency says Investing.com

   X     

3 months Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock Zacks

   X     

3 months Biogen cut at Jefferies as ‘2025 has a tough setup’ Investing.com

   X     

3 months Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript Seeking Alpha

   X     

3 months Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe Zacks

   X     

3 months Here’s Why Biogen Inc. (BIIB) is a Strong Value Stock Zacks

   X     

4 months Are Investors Undervaluing Biogen (BIIB) Right Now? Zacks

   X     

4 months Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter Seeking Alpha

   X     

4 months Biogen Beats on Q3 Earnings & Sales, Raises ’24 EPS View Zacks

   X     

4 months Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript Seeking Alpha

   X     

4 months Biogen lifts annual profit forecast as new treatments boost earnings Investing.com

   X     

4 months Biogen (NASDAQ:BIIB) Releases FY 2024 Earnings Guidance MarketBeat

   X